Clearpoint Neuro is trading 5% down at $15.00 amid broader risk-off trading on September 23, 2026. - The S&P 500 was down 0.73% and Nasdaq Composite down 1.14%; rising crude oil and Treasury yields are pressuring equity valuations. - No new company-specific announcement was identified on September 23; recent coverage references the prior Stifel Buy rating and $22 target. - The decline follows a 13.03% gain on September 22, suggesting profit-taking alongside macro weakness.